NCT03299686 - Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

November 6, 2017

Primary Completion Date

April 8, 2019

Study Completion Date

July 8, 2019

Conditions

Asthma

Interventions

DRUG

CJM112

300 mg CJM112 (Study treatment) s.c. injection received per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.

OTHER

Placebo to CJM112

Placebo to match CJM112 + standard of care treatment

Trial Locations (29)

1090

Novartis Investigative Site, Jette

2400

Novartis Investigative Site, Copenhagen NV

2650

Novartis Investigative Site, Hvidovre

4000

Novartis Investigative Site, Liège

7600

Novartis Investigative Site, Mar del Plata

9000

Novartis Investigative Site, Ghent

10117

Novartis Investigative Site, Berlin

12159

Novartis Investigative Site, Berlin

22927

Novartis Investigative Site, Großhansdorf

27607

Novartis Investigative Site, Raleigh

29303

Novartis Investigative Site, Spartanburg

34059

Novartis Investigative Site, Montpellier

55131

Novartis Investigative Site, Mainz

63110

Novartis Investigative Site, St Louis

65187

Novartis Investigative Site, Wiesbaden

69317

Novartis Investigative Site, Lyon

76100

Novartis Investigative Site, Rehovot

80206

Novartis Investigative Site, Denver

91120

Novartis Investigative Site, Jerusalem

92506

Novartis Investigative Site, Riverside

92835

Novartis Investigative Site, Fullerton

97504

Novartis Investigative Site, Medford

02115

Novartis Investigative Site, Boston

S2000DBS

Novartis Investigative Site, Santa Fe

DK 9000

Novartis Investigative Site, Aalborg

DK 5000

Novartis Investigative Site, Odense C

Unknown

Novartis Investigative Site, Jerusalem

034 01

Novartis Investigative Site, Levice

052 01

Novartis Investigative Site, Spišská Nová Ves